FR2870126B1 - Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin - Google Patents

Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin

Info

Publication number
FR2870126B1
FR2870126B1 FR0405366A FR0405366A FR2870126B1 FR 2870126 B1 FR2870126 B1 FR 2870126B1 FR 0405366 A FR0405366 A FR 0405366A FR 0405366 A FR0405366 A FR 0405366A FR 2870126 B1 FR2870126 B1 FR 2870126B1
Authority
FR
France
Prior art keywords
vaccine
expression
applications
lentiviral vector
recombinant lentiviral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR0405366A
Other languages
English (en)
French (fr)
Other versions
FR2870126A1 (fr
Inventor
Philippe Despres
Pierre Charneau
Frederic Tangy
Marie Pascale Frenkiel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut Pasteur
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0405366A priority Critical patent/FR2870126B1/fr
Application filed by Centre National de la Recherche Scientifique CNRS, Institut Pasteur filed Critical Centre National de la Recherche Scientifique CNRS
Priority to MXPA06013388A priority patent/MXPA06013388A/es
Priority to CN200580015744XA priority patent/CN1981043B/zh
Priority to CA2564934A priority patent/CA2564934C/en
Priority to BRPI0510016A priority patent/BRPI0510016B8/pt
Priority to EP11167507.0A priority patent/EP2371966B1/en
Priority to EP05748053.5A priority patent/EP1751291B1/en
Priority to JP2007517517A priority patent/JP2008508863A/ja
Priority to PCT/IB2005/001753 priority patent/WO2005111221A1/en
Priority to US11/596,675 priority patent/US20090214589A1/en
Publication of FR2870126A1 publication Critical patent/FR2870126A1/fr
Application granted granted Critical
Publication of FR2870126B1 publication Critical patent/FR2870126B1/fr
Priority to US12/929,215 priority patent/US8716013B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FR0405366A 2004-05-17 2004-05-17 Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin Expired - Lifetime FR2870126B1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
FR0405366A FR2870126B1 (fr) 2004-05-17 2004-05-17 Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
PCT/IB2005/001753 WO2005111221A1 (en) 2004-05-17 2005-05-16 Recombinant lentiviral vector for expression of a flaviviridae protein and applications thereof as a vaccine
CA2564934A CA2564934C (en) 2004-05-17 2005-05-16 Recombinant lentiviral vector for expression of a flaviviridae protein and applications thereof as a vaccine
BRPI0510016A BRPI0510016B8 (pt) 2004-05-17 2005-05-16 vetor lentiviral recombinante, composição imunogênica e uso dos mesmos como vacina
EP11167507.0A EP2371966B1 (en) 2004-05-17 2005-05-16 Recombinant lentiviral vector for expression of a Flaviviridae protein and applications thereof as a vaccine
EP05748053.5A EP1751291B1 (en) 2004-05-17 2005-05-16 Recombinant lentiviral vector for expression of a flaviviridae protein and applications thereof as a vaccine
MXPA06013388A MXPA06013388A (es) 2004-05-17 2005-05-16 Vector lentiviral recombinante para la expresion de una proteina flaviviridae y sus aplicaciones como vacuna.
CN200580015744XA CN1981043B (zh) 2004-05-17 2005-05-16 用于表达黄病毒科蛋白的重组慢病毒载体及其作为疫苗的应用
US11/596,675 US20090214589A1 (en) 2004-05-17 2005-05-16 Recombinant lentiviral vector for expression of a flaviviridae protein and applications thereof as a vaccine
JP2007517517A JP2008508863A (ja) 2004-05-17 2005-05-16 フラビウイルス科ウイルスタンパク質発現のための組換えレンチウイルスベクター、及びワクチンとしてのそれらの使用
US12/929,215 US8716013B2 (en) 2004-05-17 2011-01-07 Recombinant lentiviral vector for expression of a flaviviridae protein and applications thereof as a vaccine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0405366A FR2870126B1 (fr) 2004-05-17 2004-05-17 Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin

Publications (2)

Publication Number Publication Date
FR2870126A1 FR2870126A1 (fr) 2005-11-18
FR2870126B1 true FR2870126B1 (fr) 2009-07-17

Family

ID=34945000

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0405366A Expired - Lifetime FR2870126B1 (fr) 2004-05-17 2004-05-17 Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin

Country Status (9)

Country Link
US (2) US20090214589A1 (https=)
EP (2) EP1751291B1 (https=)
JP (1) JP2008508863A (https=)
CN (1) CN1981043B (https=)
BR (1) BRPI0510016B8 (https=)
CA (1) CA2564934C (https=)
FR (1) FR2870126B1 (https=)
MX (1) MXPA06013388A (https=)
WO (1) WO2005111221A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1050210B (en) 1999-10-12 2007-08-24 Institut Pasteur Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna
FR2870126B1 (fr) * 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
US8222029B2 (en) * 2005-05-16 2012-07-17 Institut Pasteur Lentiviral vector-based vaccine
CA2508266A1 (fr) 2005-06-20 2006-12-20 Institut Pasteur Polypeptides chimeriques et leurs applications therapeutiques contre une infection a flaviviridae
ES2423518T3 (es) 2006-12-22 2013-09-20 Institut Pasteur Células y metodología para generar virus de ARN de cadena de sentido negativo no segmentada
GB0701253D0 (en) 2007-01-23 2007-02-28 Diagnostics For The Real World Nucleic acid amplification and testing
US20110262472A1 (en) * 2008-04-22 2011-10-27 Cytos Biotechnology Ag Vaccine compositions for the treatment of dengue fever and uses thereof
EP2666477A1 (en) 2012-05-23 2013-11-27 Theravectys Lentiviral vectors containing an MHC class I promoter
EP2603799A4 (en) 2010-08-12 2014-02-12 Clontech Lab Inc SIDEFLOW ASSAYS FOR NON-DIAGNOSTIC ANALYSIS
EP3031923A1 (en) * 2014-12-11 2016-06-15 Institut Pasteur Lentiviral vector-based japanese encephalitis immunogenic composition
WO2017083291A1 (en) 2015-11-09 2017-05-18 Immune Design Corp. Compositions comprising lentiviral vectors expressing il-12 and methods of use thereof
EP3184119A1 (en) 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
SG11202004234SA (en) 2017-11-09 2020-06-29 Pasteur Institut A zika virus chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100317509B1 (ko) * 1992-07-16 2002-02-20 야스모토 토루 C형간염바이러스를분류하기위한항원성펩티드,이펩티드를포함하는키트및이펩티드를사용하는c형간염바이러스를분류하는방법
US5883081A (en) 1995-07-26 1999-03-16 The Regents Of The University Of California Isolation of novel HIV-2 proviruses
US5888767A (en) 1996-11-27 1999-03-30 The Johns Hopkins University School Of Medicine Method of using a conditionally replicating viral vector to express a gene
PT904392E (pt) 1996-10-17 2001-06-29 Oxford Biomedica Ltd Vectores retrovirais
ES2373406T3 (es) 1997-12-22 2012-02-03 Oxford Biomedica (Uk) Limited Vectores basados en el virus de la anemia infecciosa equina (vaie).
WO1999036511A2 (en) * 1998-01-16 1999-07-22 Chiron Corporation Feline immunodeficiency virus gene therapy vectors
FR2777909B1 (fr) * 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
AU4554899A (en) 1998-06-09 1999-12-30 Andrea D. Branch Novel hepatitis c virus peptides and uses thereof
US7052830B1 (en) * 1998-06-09 2006-05-30 Branch Andrea D Hepatitis C virus peptides and uses thereof
FR2794865B1 (fr) 1999-06-09 2003-04-18 Pasteur Institut Methode de detection precoce des flavivirus et ses applications
DE69941703D1 (de) 1999-10-11 2010-01-07 Pasteur Institut Lentivirale Vektoren für die Herstellung von immunotherapeutischen Zusammensetzungen
HK1050210B (en) 1999-10-12 2007-08-24 Institut Pasteur Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna
EP1092780A1 (en) 1999-10-13 2001-04-18 Boehringer Ingelheim International GmbH Recombiant, replication defective CELO virus and CELO virus DNA
CA2443290C (fr) 2001-04-04 2011-11-08 Institut Pasteur Souche neurovirulente du virus west-nile et ses applications
US20040037848A1 (en) 2001-04-06 2004-02-26 Audonnet Jean-Christophe Francis Recombinant vaccine against West Nile Virus
HU228690B1 (en) 2001-07-27 2013-05-28 Wyeth Corp West nile vaccine
CA2903126C (en) 2002-01-10 2020-03-24 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Construction of west nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by west nile virus
US7476390B2 (en) * 2002-02-26 2009-01-13 Maxygen, Inc. Flavivirus antigens
US20030194392A1 (en) 2002-04-10 2003-10-16 Pierre Charneau Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA
DE10249594A1 (de) * 2002-10-24 2004-05-13 Jassoy, Christian, Dr. Immunisierung gegen Bestandteile des Humanen Immunschwächevirus (HIV)
CA2456873A1 (en) * 2003-02-26 2004-08-26 Centre National De La Recherche Scientifique (C.N.R.S.) West nile virus proteins and genes coding the foregoing and their use in vaccinal, therapeutic and diagnostic applications
CA2432738A1 (en) 2003-02-26 2004-08-26 Philippe Despres New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications
FR2870126B1 (fr) 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
US8222029B2 (en) 2005-05-16 2012-07-17 Institut Pasteur Lentiviral vector-based vaccine
US8158413B2 (en) 2005-10-17 2012-04-17 Institut Pasteur Lentiviral vector-based vaccine

Also Published As

Publication number Publication date
EP1751291B1 (en) 2013-07-31
BRPI0510016B1 (pt) 2020-03-10
CN1981043A (zh) 2007-06-13
US20090214589A1 (en) 2009-08-27
BRPI0510016A (pt) 2007-09-18
MXPA06013388A (es) 2007-06-19
CN1981043B (zh) 2010-06-09
WO2005111221A1 (en) 2005-11-24
CA2564934A1 (en) 2005-11-24
FR2870126A1 (fr) 2005-11-18
BRPI0510016B8 (pt) 2021-05-25
EP1751291A1 (en) 2007-02-14
EP2371966B1 (en) 2015-11-25
US8716013B2 (en) 2014-05-06
EP2371966A1 (en) 2011-10-05
JP2008508863A (ja) 2008-03-27
US20110206710A1 (en) 2011-08-25
CA2564934C (en) 2014-07-08

Similar Documents

Publication Publication Date Title
BR0211623A (pt) Agentes de contraste alvos multiméricos com base em peptìdeo
FR2870126B1 (fr) Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
EP2142009A4 (en) HEMIPTERAN AND COLEOPTERAN ACTIVE TOXIN PROTEINS FROM BACILLUS THURINGIENSIS
ZA200804874B (en) Methods and proteins for the prophylactic and/or therapeutic treatment of the four serotypes of dengue virus and other flaviviruses
EP1766094A4 (en) FLUID VIRUS VACCINE COMPOSITION AND USE METHOD
CY1112848T1 (el) Αναστολεις του ιου της ηπατιτιδας c
IL181779A (en) A group of protein-based medical molecules
EP2079842A4 (en) GENERATING RECOMBINANT DNA BY SEQUENCING AND LIGATION-INDEPENDENT CLONING
EA201000424A1 (ru) Антитела к il-23
EP2086583A4 (en) COMPLETELY HUMAN ANTI-VEGF ANTIBODY AND METHOD FOR THEIR USE
EA200970586A1 (ru) Антитела к цитомегаловирусу человека (hcmv)
UA97516C2 (ru) Полностью человеческое моноклональное антитело против vap-1
EA201170353A1 (ru) Антитела против гепатита с и их применение
GB2453491A (en) Immunogenic proteins of burkholderia pseudomallei and uses thereof
DE60330708D1 (de) Impfstoff gegen das west-nile-virus
EP1778879A4 (en) ANTIBODIES TO WEST NIL VIRUS AND THERAPEUTIC AND PROPHYLACTIC USES THEREOF
DE60207053D1 (de) Rekombinante gelatineartige proteine zur verwendung als plasmaexpander
CY1118930T1 (el) Ανασυνδυασμενες πρωτεϊνες ελαστασης και μεθοδοι βιομηχανικης κατασκευης και χρηση αυτων
DE60232862D1 (de) Rekombinantes pockenvirus für chimäre proteine des menschlichen immunschwächevirus
WO2008048344A3 (en) Bacillus anthracis antigens, vaccine compositions, and related methods
EP1425039A4 (en) PEPTIDES THAT GIVE AN IMMUNE REACTION WITH THE HUMAN PAPILLOMA VIRUS
DK2206514T3 (da) Rekombinante intracellulære patogene immunogene sammensætninger og metoder til anvendelse
BRPI0906044A2 (pt) "mutante solúvel tnfrp75, proteína de fusão, sequências de dna, usos do mutante solúvel tnfrp75 e da proteína de fusão e composições farmacêuticas"

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18

PLFP Fee payment

Year of fee payment: 19

PLFP Fee payment

Year of fee payment: 20